Nesfatin-1 in cardiovascular orchestration: From bench to bedside.
Biomarker
Cardiovascular diseases
Feeding behavior
Nesfatin-1
Nucleobindin 2
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
15
01
2020
revised:
09
03
2020
accepted:
18
03
2020
pubmed:
24
3
2020
medline:
23
4
2021
entrez:
24
3
2020
Statut:
ppublish
Résumé
Since the discovery of Nesfatin-1 in 2006, intensive research was finalized to further and deeper investigate the precise physiological functions of the peptide at both central and peripheral levels, rapidly enriching the knowledge regarding this intriguing molecule. Nesfatin-1 is a hypothalamic peptide generated via the post-translational processing of its precursor Nucleobindin 2, a protein supposed to play a role in many biological processes thanks to its ability to bind calcium and to interact with different intracellular proteins. Nesfatin-1 is mainly known for its anorexic properties, but it also controls water intake and glucose homeostasis. Recent experimental evidences describe the peptide as a possible direct/indirect orchestrator of central and peripheral cardiovascular control. A specific Nesfatin-1 receptor still remains to be identified although numerous studies suggest that the peptide activates extra- and intracellular regulatory pathways by involving several putative binding sites. The present paper was designed to systematically review the latest findings about Nesfatin-1, focusing on its cardiovascular regulatory properties under normal and physiopathological conditions. The hope is to provide the conceptual basis to consider Nesfatin-1 not only as a pleiotropic neuroendocrine molecule, but also as a homeostatic modulator of the cardiovascular function and with a crucial role in cardiovascular diseases.
Identifiants
pubmed: 32201244
pii: S1043-6618(20)30184-5
doi: 10.1016/j.phrs.2020.104766
pii:
doi:
Substances chimiques
Biomarkers
0
NUCB2 protein, human
0
Nucleobindins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104766Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest All the authors declared that they have no conflicts of interest.